a phase-II peptide vaccination trial in metastatic melanoma
Therapeutic vaccination directed to induce an anti-tumoral T-cell response is a field of extensive investigation in the treatment of melanoma. However, many vaccination trials in melanoma failed to demonstrate a correlation between the vaccine-specific immune response and therapy outcome. This has been mainly attributed to immune escape by antigen loss, rendering us in the need of new vaccination targets.
Cancer Immunology, Immunotherapy : Cii, 2012, Vol 61, Issue 11, p. 2091-2103
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't